tag:blogger.com,1999:blog-7857054149675424609.post7836482568723336669..comments2024-02-24T08:58:08.581+00:00Comments on RNAi Therapeutics: Alnylam with Dominant RNAi Trigger IP Estate, but Woppmann not that Critical, ReallyDirk Hausseckerhttp://www.blogger.com/profile/18320439857875629714noreply@blogger.comBlogger7125tag:blogger.com,1999:blog-7857054149675424609.post-58579883121156794482010-04-17T19:08:02.862+00:002010-04-17T19:08:02.862+00:00Hi,
I commented on sd-rxRNAs a few times, as muc...Hi, <br /><br />I commented on sd-rxRNAs a few times, as much as possible based on the limited disclosure of the technology. What we know is that the RXi sd-rxRNAs have a size of 14bp and less. I further speculate that it is an siRNA conjugate with most likely a lipophilic group, but would not exclude transducing peptides etc.<br /><br />The efficacy data that I have seen from the presentationsDirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-88204372049848544312010-04-17T03:07:50.824+00:002010-04-17T03:07:50.824+00:00Dirk, great blog. Really appreciate the obvious ti...Dirk, great blog. Really appreciate the obvious time and effort you put in to this.<br /><br />Your attention seems to be taken with SNALP for systemic delivery but I am curious to know what your opinion is on the RXi self delivering siRNA.<br /><br />A cursory search of your blog using keyword RXi doesn't reveal much.<br /><br />I am curious whether or not you have an informed opinion on Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-86143681695655967272010-04-09T07:42:17.076+00:002010-04-09T07:42:17.076+00:00RXi's <15bp RNAi trigger IP.
I agree, the ...RXi's <15bp RNAi trigger IP.<br /><br />I agree, the Tuschls do not cover double-stranded RNAs below 15bp, and it is reasonable to assume that RXi would have generated or obtained for reasonable terms freedom-to-operate in this space. The question, of course, how easy it is to find potent siRNAs in this areas since RNAi potency is known to generally decrease 'dramatically' once Dirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-32335896163314577822010-04-09T07:26:02.518+00:002010-04-09T07:26:02.518+00:00Baulcombe and Hamilton patent...Unfortunately, the...Baulcombe and Hamilton patent...Unfortunately, the Nature Biotech article does not mention which patent application has just issued, but the main claim of the equivalent plant-specific patent (see below) states that(a) a small RNA has to be detected, and then (b) this has to be correlated with silencing of a target gene. If only (a), then I would have said that microRNA Dx companies could have Dirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-39735754582284518932010-04-08T22:35:40.790+00:002010-04-08T22:35:40.790+00:00Dirk
Thanks for your excellent ongoing analysis o...Dirk<br /><br />Thanks for your excellent ongoing analysis of RNAi therapeutics. Yours is the first blog I check every morning.<br /><br />In today's webcast from RXII, it was stated that their technology does not lie under the purview of the Tuschels since their technology only involves 14 or fewer nucleotides. The presenter also claimed complete freedom in the space.<br /><br />Could you Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-386857431202713812010-04-08T21:43:24.440+00:002010-04-08T21:43:24.440+00:00Hi Dirk,
Got any thoughts on Baulcombe patent bei...Hi Dirk,<br /><br />Got any thoughts on Baulcombe patent being extended to cover siRNA in mammals? (ref Nature flyer below)<br /><br />Regards,<br />Mike<br /><br />RNAi patent jolt<br />- Nature Biotechnology 28(4):300 (2010)<br />The US Patent and Trademark Office has issued a patent for detection of RNA-mediated gene silencing to Sir David Baulcombe, University of Cambridge, and Andrew Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-25850113513533622382010-04-08T10:15:04.328+00:002010-04-08T10:15:04.328+00:00Hi Dirk
I am an attorney, however, I do not do in...Hi Dirk<br /><br />I am an attorney, however, I do not do intellectual property.<br /><br />Having read the actual claims, I agree with your analysis, although I am, of course, not qualified to comment how easy/difficult it is to work around the specific sequences in the claims.<br /><br />It is disappointing (and worrisome) to see Alnylam adopt spin tactics reminiscent of some of its competitorsAnonymousnoreply@blogger.com